Eli Lilly plans to launch its weight-loss pill in Europe and the United Kingdom during the second half of 2026 or in early 2027.
The pharmaceutical company intends to focus initially on patients who pay directly for treatment through telehealth platforms. This approach will be similar to the strategy Lilly has followed in the United States.
Europe and Britain Among the Next Launch Markets
Patrik Jonsson, executive vice president of Eli Lilly’s international operations, said Europe and Britain are expected to be among the next markets to receive the weight-loss drug.
The planned expansion follows recent regulatory approvals in the United States and the United Arab Emirates.
Lilly intends to introduce the treatment as soon as it receives the necessary European and British regulatory approvals.
Eli Lilly Targets the Telehealth Market
The company plans to work with telehealth providers to distribute its weight-loss pill directly to patients.
According to Jonsson, most obesity treatments outside the United States are currently paid for by patients rather than national healthcare systems.
This makes the private telehealth market an important initial opportunity for Eli Lilly’s European weight-loss business.
Patients could potentially access the medicine through online consultations, digital pharmacies and other direct-to-consumer healthcare services.
Direct-to-Patient Strategy Expands Beyond the US
Eli Lilly’s strategy reflects its wider effort to build a consumer-focused obesity treatment business outside the United States.
The company plans to use telehealth providers, e-commerce platforms and direct-to-patient distribution channels to improve access to its medicines.
Jonsson said Lilly is applying lessons learned from the rapid development of the US obesity market.
The approach could help the company introduce the drug more quickly while negotiations with national healthcare systems continue.
Public Reimbursement Remains a Priority
Although Lilly will initially target patients paying out of pocket, the company will also seek public reimbursement across European markets where possible.
Government coverage could eventually make the treatment available to a much larger number of patients.
However, negotiations with European healthcare authorities may become more complicated because of changing US drug-pricing policies.
Trump Drug-Pricing Policy Could Affect Negotiations
President Donald Trump’s most-favoured-nation drug-pricing policy aims to connect certain US medicine prices with those paid in other countries.
The policy could affect the prices Eli Lilly is willing to accept when launching new medicines in Europe and Britain.
Jonsson said public coverage remains the company’s objective wherever it can be secured. However, he acknowledged that the most-favoured-nation framework will influence future drug launches.
Lilly Seeks Prices Consistent With MFN Agreement
Eli Lilly reached an agreement with the Trump administration last year to offer most-favoured-nation pricing on new medicines.
Under Lilly’s interpretation of the framework, international prices would be linked to net US prices while also accounting for differences in national income levels.
The company is expected to pursue reimbursed European prices that remain consistent with that approach.
Balancing affordability, public healthcare access and US pricing requirements could therefore become an important part of Lilly’s European weight-loss pill launch.swa
